

View the current Pharmacopeial Forum (PF) Table of Contents. For older PF tables of contents, [visit our archive](#).

Select from the below links to access PF content. A free resource, PF visitors must create a user name and password.

PF 47(3) Table of Contents Publish date: [May 3, 2021]

In-Process Revision

[In-Process Revision Introduction](#)

General Test and Assay Chapter

[<771> Ophthalmic Products - Quality Tests \(USPNF 2022 ISSUE 3\)](#)

[<781> Optical Rotation \(USPNF 2022 ISSUE 3\)](#)

[<787> Subvisible Particulate Matter in Therapeutic Protein Injections \(USPNF 2022 ISSUE 3\)](#)

[<789> Subvisible Particulate Matter in Ophthalmic Solutions \(USPNF 2022 ISSUE 3\)](#)

[<831> Refractive Index \(USPNF 2022 ISSUE 3\)](#)

Reagents, Indicators, and Solutions

Reagent Specifications

[Cesium Carbonate \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Deuterated Acetone \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Deuteriochloroform \(USPNF 2022 ISSUE 3\)](#)

[Potassium Hexafluorophosphate \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Triphenyl Phosphate \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

Volumetric Solutions

[0.1 N Ferric Ammonium Sulfate VS \(USPNF 2022 ISSUE 3\)](#)

[0.1 N Sulfuric Acid VS \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

Chromatographic Columns

[L127 \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

Description and Solubility

[Description and Solubility \(USPNF 2022 ISSUE 3\)](#)

USP Monographs

[Abacavir, Lamivudine, and Zidovudine Tablets \(USPNF 2022 ISSUE 3\)](#)

[Amantadine Hydrochloride Tablets \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Calcium Ascorbate \(USPNF 2022 ISSUE 3\)](#)

[Codeine \(USPNF 2022 ISSUE 3\)](#)

[Diphenhydramine Hydrochloride Oral Powder \(USPNF 2022 ISSUE 3\)](#)

[Enzacamene \(USPNF 2022 ISSUE 3\)](#)

[Esomeprazole Sodium \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Esomeprazole Sodium for Injection \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Ethionamide \(USPNF 2022 ISSUE 3\)](#)

[Etravirine \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Etravirine Tablets \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Fluorouracil Injection \(USPNF 2022 ISSUE 3\)](#)

[Fluticasone Propionate \(USPNF 2022 ISSUE 3\)](#)

[Diluted Isosorbide Mononitrate \(USPNF 2022 ISSUE 3\)](#)

[Omega-3-Acid Ethyl Esters \(USPNF 2022 ISSUE 3\)](#)

[Oxycodone Hydrochloride Tablets \(USPNF 2022 ISSUE 3\)](#)

[Polyethylene Glycol 3350 for Oral Solution \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Prasugrel Hydrochloride \(USPNF 2022 ISSUE 3\)](#)

[Propranolol Hydrochloride Injection \(USPNF 2022 ISSUE 3\)](#)

[Saquinavir Mesylate \(USPNF 2022 ISSUE 3\)](#)

[Trichlormethiazide \(USPNF 2022 ISSUE 3\)](#)

[Valacyclovir Hydrochloride \(USPNF 2022 ISSUE 3\)](#)

[Valganciclovir for Oral Solution \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

Dietary Supplement Monographs

[Bael Tree Fruit \(USPNF 2022 ISSUE 3\)](#)

[Bael Tree Fruit Dry Extract \(USPNF 2022 ISSUE 3\)](#)

[Bael Tree Fruit Powder \(USPNF 2022 ISSUE 3\)](#)

[Cranberry Fruit Juice Dry Extract Capsules \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Dong Quai Root \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Dong Quai Root Powder \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Fish Oil Omega-3 Acid Ethyl Esters Concentrate \(USPNF 2022 ISSUE 3\)](#)

[Fish Oil Containing Omega-3 Acids \(USPNF 2022 ISSUE 3\)](#)

[Fish Oil Containing Omega-3 Acids Capsules \(USPNF 2022 ISSUE 3\)](#)

[Fish Oil Containing Omega-3 Acids Delayed-Release Capsules \(USPNF 2022 ISSUE 3\)](#)

[L-alpha-Glycerolphosphorylcholine \(USPNF 2022 ISSUE 3\)](#)

[Krill Oil \(USPNF 2022 ISSUE 3\)](#)

[Krill Oil Capsules \(USPNF 2022 ISSUE 3\)](#)

[Krill Oil Delayed-Release Capsules \(USPNF 2022 ISSUE 3\)](#)

[Lactiplantibacillus plantarum \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Ligilactobacillus salivarius \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

[Conjugated Linoleic Acids-Free Fatty Acids \(USPNF 2022 ISSUE 3\)](#)

[Omega-3 Acid Triglycerides \(USPNF 2022 ISSUE 3\)](#)

[Omega-3 Free Fatty Acids \(USPNF 2022 ISSUE 3\)](#)

[Streptococcus thermophilus \[NEW\] \(USPNF 2022 ISSUE 3\)](#)

Stage 2 Harmonization

[Stage 2 Harmonization Introduction](#)

[<788> Particulate Matter in Injections \(USPNF 2022 ISSUE 3\)](#)

Stimuli to The Revision Process

[Filling the Pharmacopeial Gaps of Visual Inspection: Toward Standardization and Consistency of Visible Particle Testing \[NEW\]](#)